Drug Trial Radar · NCT06593600
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Nov 13, 2024
Primary completion
May 6, 2026
Study completion Jul 8, 2026
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on participants with POTS. The aim of the study is to see how safe, tolerable, and effective the study drug is. The study is looking at several other research questions, including: * How the study drug changes heart rate and blood pressure in participants with POTS * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * How the study drug affects symptoms associated with POTS
Conditions
- Postural Orthostatic Tachycardia Syndrome (POTS)
Interventions
REGN7544Drug
Subcutaneous (SC) administration
PlaceboDrug
SC administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Heart Rate (HR) from supine to standing (DeltaHR)Time frame: At Day 8
- Change from baseline in DeltaHR-avgTime frame: At day 29
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
Mercy Gilbert Medical Center
Gilbert, Arizona
North County Neurology Associates
Carlsbad, California
Stanford University
Palo Alto, California
Southern California Heart Specialists
Pasadena, California
Yale University
New Haven, Connecticut
Innovative Research of West Florida, Inc.
Clearwater, Florida
Indiana University Health Neuroscience Center
Indianapolis, Indiana
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Saint Luke's MidAmerica Heart Institute
Kansas City, Missouri
New York University Langone
New York, New York
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern
Dallas, Texas
University of Utah
Salt Lake City, Utah
University of Calgary
Calgary, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.